<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027638</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-01027</org_study_id>
    <secondary_id>CDR0000069051</secondary_id>
    <secondary_id>NCI-G01-2029</secondary_id>
    <nct_id>NCT00027638</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to&#xD;
      the tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who&#xD;
      have metastatic neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of thalidomide in patients with metastatic low-grade&#xD;
           neuroendocrine tumors.&#xD;
&#xD;
      OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Tumor</condition>
  <condition>Lung Cancer</condition>
  <condition>Neoplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed low-grade neuroendocrine tumors&#xD;
&#xD;
               -  Carcinoid tumors&#xD;
&#xD;
               -  Islet cell tumors&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Progression of disease within past 4 weeks by radiological evidence&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion by CT scan or MRI&#xD;
&#xD;
               -  Bone metastasis not considered measurable if only site of disease&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception for 4 weeks before,&#xD;
             during, and for 4 weeks after study&#xD;
&#xD;
          -  No grade 2 or greater neuropathy&#xD;
&#xD;
          -  No other clinical circumstances that would preclude study&#xD;
&#xD;
          -  No other prior malignancy except:&#xD;
&#xD;
          -  Non-melanoma skin cancer&#xD;
&#xD;
          -  Other cancer that has been curatively treated, has had no evidence of recurrence&#xD;
             within the past 5 years, and is at low risk for recurrence&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No more than 1 prior systemic therapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy regimen&#xD;
&#xD;
          -  No other concurrent therapeutic agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard B. Saltz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

